Observational studyBMC infectious diseases2026
Serum mass spectral fingerprints with machine learning for early discrimination of infectious pneumonia in the emergency department.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCommunity–acquired pneumonia is a major cause of emergency department visits, hospitalization, and death. In the emergency department, decisions to diagnose pneumonia and initiate antibiotics are typically guided by clinical assessment (symptoms and physical examination), chest imaging, and laboratory tests including inflammatory markers. However, discrimination between infectious pneumonia and non–infectious conditions remains only moderately accurate, and imaging is not always immediately available. There is therefore a need for simple, rapid point–of–care testing (POCT) that can screen for infectious pneumonia early in the evaluation. Serum metabolomics using liquid chromatography–mass spectrometry (LC–MS) is a potential POCT approach, but most prior studies have focused on relatively small panels of identified metabolites and have made limited use of unidentified spectral information. We therefore applied machine learning to full–scan serum mass spectral fingerprints, including unidentified peaks, to distinguish infectious pneumonia from non–infectious cases in the emergency department setting.
methodsWe conducted a single–center proof–of–concept observational study using a serum biobank from adult patients in a secondary–care ED in Japan. To evaluate the diagnostic models, we selected from this biobank 20 clearly non–infectious cases without gray–zone presentations and 20 cases of clinically diagnosed infectious pneumonia based on prespecified stringent clinical criteria. We performed LC–MS–based profiling to quantify metabolites and to acquire mass spectral fingerprints. Two machine–learning models were evaluated with stratified 5–fold cross–validation, and diagnostic performance for distinguishing these predefined groups was assessed using the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity.
resultsWe analyzed 20 cases of infectious pneumonia and 20 non–infectious cases. The metabolite model achieved an AUC of 0.885 (95% confidence interval 0.754–0.985) for discriminating infectious pneumonia from non–infectious cases, whereas the mass spectral fingerprint model showed perfect discrimination in internal cross–validation (AUC = 1.000).
conclusionsIn this proof–of–concept study, machine–learning models trained on serum mass spectral fingerprints demonstrated promising performance in discriminating infectious pneumonia from non–infectious conditions in this selected cohort. This approach may serve as a foundation for future POCT applications, although larger multicenter external validation studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.